Further longitudinal analysis of the natural course of MPO and MMP-9 levels in CAD with and without OSA, the impact of CPAP treatment on these biomarkers as well as the association of changes from baseline with the major adverse outcomes in the RICCADSA cohort are in progress. Here, MMP9 is linked to obstructive sleep apnea syndrome.